Table 1 Summary clinical characteristics of included patients
From: A genomic-clinicopathologic nomogram for predicting overall survival of hepatocellular carcinoma
Category | Experimental group (ICGC, n = 232) | Validation group (TCGA, n = 369) |
|---|---|---|
Age | ||
< 65 | 83 (35.8%) | 218 (59.1%) |
≥ 65 | 149 (64.2%) | 151 (40.9%) |
Gender | ||
Male | 171 (73.7%) | 248 (67.2%) |
Female | 61 (26.3%) | 121 (32.8%) |
Vital status | ||
Alive | 189 (81.5%) | 243 (65.9%) |
Dead | 43 (18.5%) | 126 (34.1%) |
Race | ||
White | 0 | 185 (50.1%) |
Black | 0 | 17 (4.6%) |
Asian | 232 (100%) | 157 (42.6%) |
unknown | 0 | 10 (2.7%) |
Tumor stage | ||
I | 36 (15.5%) | 172 (46.6%) |
II | 106 (45.7%) | 84 (22.8%) |
III | 71 (30.6%) | 85 (23.0%) |
IV/ | 19 (8.2%) | 5 (1.4%) |
unknown | 0 | 23 (6.2%) |
T stage | ||
T1 | NA | 181 (49.1%) |
T2 | NA | 92 (24.9%) |
T3 | NA | 80 (21.7%) |
T4 | NA | 13 (3.5%) |
unknown | NA | 3 (0.8%) |
M stage | ||
M0 | NA | 266 (72.1%) |
M1 | NA | 4 (1.1%) |
unknown | NA | 99 (26.8%) |
N stage | ||
N0 | NA | 251 (68.0%) |
N1 | NA | 4 (1.1%) |
unknown | NA | 114 (30.9%) |
Prior malignancy | ||
Yes | 30 (12.9%) | NA |
No | 202 (87.1%) | |